Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]

Peer Review reports

Original Submission
4 Feb 2022	Submitted	Original manuscript
24 Feb 2022	Reviewed	Reviewer Report - Kirsty Loudon
17 Mar 2022	Author responded	Author comments - Xuan Ying Poh
Resubmission - Version 2
17 Mar 2022	Submitted	Manuscript version 2
Publishing
23 Apr 2022	Editorially accepted
16 Jun 2022	Article published	10.1186/s13063-022-06345-2

Back to article page